drugset / Trial / NCT04460001

Injection of Ranibizumab Versus Combination of Ranibizumab and Triamcinolone Acetate for (CRVO)

NCT04460001

Phase 2/3 Unknown 100 enrolled Assiut University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To compare the clinical effectiveness of ranibizumab and combination of ranibizumab and triamcinolone for the treatment of macular oedema secondary to CRVO

Timeline

Start
2019-05-16
Primary completion
2021-08-01
Completion
2021-12-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ranibizumab Monoclonal antibody Intravitreal
Comparator Triamcinolone Other / unclassified Intravitreal

Indications

No indication recorded.